Novo Nordisk to pay up to $2.6bn for rights to Hengrui Pharma weight-loss drug

The license agreement with China’s Hengrui is for HRS-1596, a phase 1-ready glucagon-like peptide-1 receptor (GLP-1R) and gastric inhibitory polypeptide receptor NASDAQ:GIPR dual agonist, with potential for once-weekly oral dosing.Denmark’s Novo will obtain exclusive rights to develop, manufacture…